Politics
White House Denies Trump Access to Obesity Drug
The White House denied reports that President Trump had access to the unapproved obesity drug retatrutide under the FDA’s compassionate use program. The denial came in response to a recent report suggesting such access.
Coverage timeline — 1 article
The Hill
White House officials on Tuesday shot down a report speculating that President Trump gained access to the retatrutide weight-loss drug under the Food and Drug Administration’s (FDA) “compassionate use program.” The retatrutide drug is manufactured by Eli Lilly and is not FDA approved, however, one p
2026-06-23 22:20 UTC